Biotechnology and Pharmaceuticals · global
Lupin Places Two New Cancer Drugs Into a New Company: Kaveri Takes Over Clinical Development and Fundraising
The PRMT5 and SOS1 inhibitors will be advanced into global trials by the newly established Kaveri; Lupin retains more than 80% ownership, but there are still insufficient details to assess efficacy, safety, and follow-on funding.
Two clinical-stage cancer drug candidates now have a new vehicle dedicated to raising funds and developing them. Indian pharmaceutical company Lupin has spun out the PRMT5 inhibitor LNP7457 and the SOS1 inhibitor LNP8701 into U.S. startup Kaveri Therapeutics, hoping that an independent company structure will attract external capital and accelerate global trials.
The transaction was carried out by Lupin’s wholly owned subsidiary Lupin Inc., with Kaveri obtaining exclusive rights to the two programs. Lupin’s announcement said only that the company would retain a “significant equity stake” and provide seed funding; HDFC SKY, citing stock exchange filings, reported that the license is a perpetual arrangement and that Lupin received approximately 82.2% ownership of Kaveri through 332,000 shares of common stock. The two assets were valued at a combined US$1.6 million, and the transaction was completed on July 20.
LNP7457 targets protein arginine methyltransferase 5 (PRMT5), an enzyme involved in gene expression and RNA processing. Some tumors may be more sensitive to PRMT5 inhibition because of specific gene deletions or metabolic contexts. LNP8701 inhibits SOS1; SOS1 helps activate RAS signaling, so blocking it is regarded as a way to intervene upstream in RAS-driven cancers and explore combination treatments.
Kaveri said it will initially focus on lung cancer, pancreatic cancer, ovarian cancer, and solid tumors associated with the central nervous system, using a biomarker-driven development strategy. This means the trials must answer not only whether the drugs can shrink tumors, but also which molecular characteristics are sufficient to identify patients more likely to benefit.
Lupin said positive clinical data for LNP7457 and LNP8701 were presented at the 2025 and 2026 American Society of Clinical Oncology annual meetings, respectively. However, the current announcement did not disclose the number of participants, doses, response rates, adverse events, or trial phases, nor did it provide a start date for the next trial; the available information is insufficient to compare the efficacy or safety of the two drugs with similar therapies.
This spinout is not an outright sale of the assets, but rather concentrates the research and development risks and fundraising needs in an independent company. Kaveri will be led by CEO Kristi Jones and Chief Medical Officer Robert Pierce and will separately seek funding for clinical development. Lupin still holds a majority stake, and whether the structure can truly spread costs, attract specialist investors, and advance more compelling trials will depend on financing terms and comprehensive clinical data to come.